Effects of cyclosporin and cremophor on working rat heart and incidence of myocardial lipid peroxidation

Pharmacology

Volumn 52, Issue 1, 1996, Pages 1-7

  Tatou, Etienne ^a   Mossiat, Claude ^b   Maupoil, Véronique ^b   Gabrielle, François ^a   David, Michel ^a   Rochette, Luc ^b  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b Facultés de Médccine et dc Pharmacie   (France)

Author keywords

Arrhythmias; Cyclosporin; Lipid peroxidation; Working rat heart

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; CREMOPHOR; CYCLOSPORIN; DRUG VEHICLE; IMMUNOSUPPRESSIVE AGENT; MACROGOL DERIVATIVE; REACTIVE OXYGEN METABOLITE; CHLORMETHINE; CYCLOSPORIN A; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANALYSIS OF VARIANCE; ANIMAL; AORTA; ARTICLE; CHEMICALLY INDUCED DISORDER; CORONARY ARTERY BLOOD FLOW; DRUG EFFECT; DRUG POTENTIATION; HEART; HEART MUSCLE ISCHEMIA; HEART TRANSPLANTATION; HEART VENTRICLE FIBRILLATION; LIPID PEROXIDATION; MALE; METABOLISM; RAT; TACHYCARDIA; VEHICLES; WISTAR RAT; ANIMAL TISSUE; AORTA FLOW; CONTROLLED STUDY; HEART FUNCTION; HEART MUSCLE; ISOLATED HEART; NONHUMAN; PRIORITY JOURNAL;

3,4-METHYLENEDIOXYAMPHETAMINE; ANALYSIS OF VARIANCE; ANIMALS; AORTA; CORONARY CIRCULATION; CYCLOSPORINE; DRUG SYNERGISM; HEART; HEART TRANSPLANTATION; IMMUNOSUPPRESSIVE AGENTS; LIPID PEROXIDATION; MALE; MYOCARDIAL ISCHEMIA; POLYETHYLENE GLYCOLS; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; TACHYCARDIA; VEHICLES; VENTRICULAR FIBRILLATION;

EID: 0029661705     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000139354     Document Type: Article

References (33)

1. Ryffel B: Pharmacology of cyclosporin., VI., Cellular activation: Regulation of intracellular events by cyclosporin., Pharmacol Rev 1989;41: 407-422.
2. Nahmann NS Jr, Cosio FG, Mahan JD, Henry ML, Ferguson RM: Cyclosporin nephrotoxicity in spontaneously hypertensive rats., Transplantation 1988;45:768-772.
3. Aszalos A: Cyclosporin: Some aspects of its mode of action., J Med 1988;19:297-316.
4. Mankad P, Spatenka J, Slavik Z, O’Neil G, Chester A, Yacoub M: Acute effects of cyclosporin and cre-mophor EL on endothelial function and vascular smooth muscle in the isolated rat heart., Cardiovasc Drugs Ther 1992:6:77-83.
5. Bril A, Abadie C, Ben Baouli A, Maupoil V, Rochette L: Absence of relationship between antiarrhyth-mic effects of antidepressant drugs and lipid peroxidation., Pharmacology 1993;46:23-32.
6. Bossaler C, Forstermann U, Hertcl R: Cyclosporin A inhibits endothelium-dependent vasodilatation and vascular prostacyclin production., Eur J Pharmacol 1989:165:165-169.
7. Rego A, Vargas R., Wroblewska B: Attenuation of vascular relaxation and cyclic GMP responses by cyclosporin A., J Pharmacol Exp Ther 1990:252:165-170.
8. Locher R., Huss R., Vetter W: Potentiation of vascular smooth muscle cell activity by cyclosporin A., Eur J Clin Pharmacol 1991:41:297-301.
9. Nayler WG, Gu XH., Casley DJ, Pa-nagiotopoulos S, Liu J., Mottram PL: Cyclosporin increases endothelin-1 binding site density in cardiac cell membranes., Biochem Biophys Res Commun 1989;163:1270-1274.
10. Barros EJG, Boim MA, Ajzen H, Ramoso L, Schor N: Glomerular hemodynamic and hormonal participation on cyclosporin nephrotoxicity., Kidney Int 1987;32:19-25.
11. Barros EJG, Boim MA, Draibe SA, Sigulcm D, Ramos OL, Schor N: Effects of cyclosporin on renal microcirculation., Nephrol Dial Transplant 1987;2:261-265.
12. Perico N, Zoja C, Benigni A, Ghilardi F, Gualandris L, Remuzzi G: Effect of short-term cyclosporin administration in rats on renin-angiotensin and thromboxane A2: Possible relevance to the reduction in glomerular filtration rate., J Pharmacol Exp Ther 1986;239:229-235.
13. Dzau VJ: Implications of local angiotensin production in cardiovascular physiology and pharmacology., Am J Cardiol 1987;59:59-65.
14. Unger T, Gohlke P., Ganten D, Lang RE: Converting enzyme inhibitors and their effects on the renin-angiotensin system of the blood vessel wall., J Cardiovasc Pharmacol 1989; 13(suppl):S8-S16.
15. Rochette L, Didier JP, Moreau D, Bralel J: Effect of substrate on release of myocardial norepinephrine and ventricular arrhythmias following rcperfusion on the ischemic isolated working rat heart., J Cardio-vasc Pharmacol 1980:2:267-279.
16. Maupoil V., Rochette L: Evaluation of free radical and lipid peroxide formation during global ischemia and rcperfusion in isolated perfused rat heart., Cardiovasc Drugs Ther 1988;2:615-621.
17. Fahr A: Cyclosporin clinical pharmacokinetics., Clin Pharmacokinet 1993;24:472-495.
18. Xue H, Bukoski D., McCarron DA., Bennett WM: Induction of contraction in isolated rat aorta by cyclosporin., Transplantation 1987;43: 715-718.
19. Golub MS, Berger ME: Direct augmentation by cyclosporin A of the vascular contractile response to nerve stimulation., Hypertension 1987:9:96-100.
20. McKenzie N, Devineni R, Venzina W., Keown P., Stiller C: The effect of cyclosporin on organ blood flow., Transplant Proc 1985; 17:1973-1975.
21. Mihatsch MJ., Thiel G, Basler V., Ryffel V, Landmann J, Von Overbeck J, Zollinger HU: Morphological patterns in cyclosporin-treated renal transplant recipients., Transplant Proc 1985; 17(suppl 1): 101-116.
22. Myers BD: What is cyclosporin nephrotoxicity? Transplant Proc 1989;21:1430-1432.
23. Kon V, Sugiura M., Inagami T, Har-vie BR., Ichikawa I, Hoover RL: Role of endothelin in cyclosporin-induced glomerular dysfunction., Kidney Int 1990;37:1487-1491.
24. Voss BL, Hamilton KK., Scott Samara EN, McKee PA: Cyclosporin suppression of endothelial prostacyclin generation., A possible mechanism for nephrotoxicity., Transplantation 1988;4:793-796
25. Zoja C, Furci L, Ghilardi F., Zilio P., Benigni A, Remuzzi G: Cyclosporin-induced endothelial cell injury., Lab Invest 1986;55:55-62.
26. Perico N, Benigni A, Bosco E, Rossini M, Orisio S, Ghilardi F, Picci-nelo A, Remuzzi G: Acute cyclosporin A nephrotoxicity in rats: Which role for renin angiotensin system and glomerular prostaglandins? Clin Nephrol 1986;25:S83-S88.
27. Auch-Schwclk W, Bossaller C, Gotze S, Thclen J, Fleck E: Endothelial and vascular smooth muscle function after chronic treatment with cyclosporin A., J Cardiovasc Pharmacol 1993;21:435-440.
28. Banijamali HS, ter Keurs MHC, Paul LC, ter Keurs HEDJ: Excitation-concentration coupling in rat heart: Influence of cyclosporin A., Cardiovasc Res 1993;27:1845-1854.
29. Aso Y, Tajima A, Suzuki K, Ohta-wara Y, Ohtan N, Hatam M, Tsu-kada T: Nephrotoxicity in rats receiving cyclosporin., Biochemical and morphological study., Jpn J Urol 1985;76:1454-1459.
30. Insclmann G, Blank M., Baumann K: Cyclosporin A induced lipid peroxidation in microsomes and effect on active and passive glucose transport by brush border membrane vesicles or rat kidney., Res Commun Chem Pathol Pharmacol 1988;62: 207-220.
31. Kumano K, Yoshida K, Iwamura M, Endo T, Sakai T, Nakamura K, Kuwao T: The role for reactive oxygen species in cyclosporin A induced nephrotoxicity in rats., Transplant Proc 1989;1:941-945.
32. Chancercllc Y, de Lorgeril M, Viret R, Chiron B, Dureau G, Renaud S, Kergonou JF: Increased lipid peroxidation in cyclosporin-treated heart transplant recipients., Am J Cardiol 1991:68:813-816.
33. Duchen MR., McGuinncss O, Brown LA., Crompton M: On the involvement of a cyclosporin A sensitive mitochondrial pore in myocardial rcperfusion injury., Cardiovasc Res 1993:27:1790-1794.